




Supplement Figure 1. Funnel plot for publication bias in studies reporting *P. aeruginosa* eradication




Supplement Figure 2. Funnel plot for publication bias in studies reporting the change in *P. aeruginosa* sputum density




Supplement Figure 3. Funnel plot for publication bias in studies reporting the change in FEV₁% predicted




Supplement Figure 4. Funnel plot for publication bias in studies reporting the number of hospital admissions




Supplement Figure 5. Funnel plot for publication bias in studies reporting the days of hospital admission




Supplement Figure 6. Funnel plot for publication bias in studies reporting the number of exacerbations




Supplement Figure 7. Funnel plot for publication bias in studies reporting clinical improvement




Supplement Figure 8. Funnel plot for publication bias in studies reporting non-fatal adverse events




Supplement Figure 9. Funnel plot for publication bias in studies reporting respiratory non-fatal adverse events




Supplement Figure 10. Funnel plot for publication bias in studies reporting the development of tobramycin resistance




Supplement Figure 11. Leave-one-out sensitivity analysis for *P. aeruginosa* eradication




Supplement Figure 12. Leave-one-out sensitivity analysis for the change in *P. aeruginosa* sputum density




Supplement Figure 13. Leave-one-out sensitivity analysis for the change in FEV₁% predicted




Supplement Figure 14. Leave-one-out sensitivity analysis for the number of hospital admissions




Supplement Figure 15. Leave-one-out sensitivity analysis for the days of hospital admission




Supplement Figure 16. Leave-one-out sensitivity analysis for the number of exacerbations




Supplement Figure 17. Leave-one-out sensitivity analysis for clinical improvement



Supplement Figure 18. Leave-one-out sensitivity analysis for non-fatal adverse events



Supplement Figure 19. Leave-one-out sensitivity analysis for respiratory non-fatal adverse events



Supplement Figure 20. Leave-one-out sensitivity analysis for the development of tobramycin resistance

